Suchergebnisse

The charge to link academic research to good ends is one that has, lately, been linked to federal funding for all types of political science research, to include public adminsitration research. Public administration researchers are proded frequently to develop "points for practitioners" or "recommendations for practice" from their academic research projects. The purpose of these points is to provide practitioners with tools to improve government services and, it is hoped, to provide more good in their communities. Should public administration researchers concern themselves with the good that their research could produce? In this disputatio, I take up this question to suggest that the good we provide as public administration researchers is a limited, community level, good.

AbstractIn this article, I probe an example of high‐technology medicine as a case study in the problems of the regulation of advancing technology. Specifically, I address the implications of pharmacogenomics—an emerging form of population‐based health care intervention—for public policies designed to eliminate racial disparities in health. Using the case of BiDil, a historical precursor to pharmacogenetic technology, I offer a framework for further studies of high‐technology medicine in which policy analysis is part of a social review based on the justice standard of ex ante mutual advantage. It is the contention in this article that the most just and reasonable deployment of pharmacogenomics is as a compensatory tool to alleviate health disparities.